Posted by Michael Wonder on 29 Dec 2020
European Medicines Agency validates Bristol Myers Squibb’s application for Zeposia (ozanimod) for the treatment of ulcerative colitis
28 December 2020 - Marketing authorisation application is supported by positive results from the pivotal Phase 3 True North trial evaluating oral Zeposia (ozanimod) in adults with moderately to severely active ulcerative colitis.
Bristol Myers Squibb today announced that the EMA has validated its marketing authorisation application for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis.
